. 2023 Jan 3;80(2):380–391. doi: 10.1007/s12020-022-03281-8

Table 2.

Thyroid function and antibody profile of patients with incident anti-TPO or anti-Tg positivity at reassessment

Patient number	Sex/Age	On admission					COVID-19 treatment	3-month assessment					6-month assessment
Patient number	Sex/Age	TSH^a	fT4^a	fT3^a	Anti-TPO^b	Anti-Tg^b	COVID-19 treatment	TSH^a	fT4^a	fT3^a	Anti-TPO^b	Anti-Tg^b	TSH^a	fT4^a	fT3^a	Anti-TPO^b	Anti-Tg^b
1	M/58	0.55	16	2.9	64.9	2957	IFN + RIB + DEX	0.02	21	7.2^c	100.1	2794	1.9	14	5.4	112.2	2819
2	F/61	0.61	19	4.1	44.4	5.1	IFN + RIB	0.45	18	4.7	129.7	5.62	0.60	18	5.1	131.9	5.7
3	F/67	1.3	18	N/A	45.5	4.3	IFN + RIB	1.7	17	5.3	148.2	6.6	1.1	16	6.1	56.8	7.2
4	F/61	1.2	17	3.5	6.9	4.9	IFN + RIB	2.8	20	5.0	141.2	8.3	1.9	16	4.3	27.2	20.0
5	M/51	2.2	16	4.6	97.1	4.8	IFN + RIB	1.7	20	5.6	122.4	3.7	2.8	17	5.7	68.0	6.4
6	M/55	1.6	15	3.3	89.3	21.1	REM	3.7	14	3.7	197.9	38.0	N/A
7	M/21	1.1	17	4.4	99.9	6.6	IFN + RIB	0.47	19	5.2	128.5	9.7	N/A
8	M/45	1.6	13	4.9	82.9	9.0	IFN + REM + DEX	1.6	11	5.1	108.1	6.2	N/A
9	F/62	0.98	14	3.3	198.9	43.5	Nil	1.2	15	4.2	264.3	839	N/A

M male, F female, TSH thyroid-stimulating hormone (mIU/L), fT4 free thyroxine (pmol/L), fT3 free triiodothyronine (pmol/L), anti-TPO anti-thyroid peroxidase antibody (units), anti-Tg anti-thyroglobulin antibody (units), COVID-19 coronavirus disease 2019, IFN interferon beta-1b, RIB ribavirin, REM remdesivir, DEX dexamethasone, N/A not available

Age expressed in years

^aReference ranges: TSH 0.35–4.8 mIU/L, fT4 12–23 pmol/L, fT3 3.2–6.5 pmol/L

^bPositive anti-TPO defined by >100 units; positive anti-Tg defined by >100 units

^cHis anti-TSHR titre was 0.8 IU/L, i.e. negative

Values out of reference ranges are in bold